ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy: a case report

Clicks: 322
ID: 128902
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #11 of 54 articles by views in proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
Reference Key
ayl2015turkishruxolitinib Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Meltem Aylı, Muhit Özcan, Güldane Cengiz Seval
Are you one of these authors? Claim your profile
Journal proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017
Year 2015
DOI
10.4274/tjh.2013.0338
URL
http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-70370&look4=
Keywords
ruxolitinib primary myelofibrosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.